#Canada #Toronto #Aesthetics #Croma-Pharma #Renellence

Strengthening Ties: Croma-Pharma GmbH and Renellence Join Forces in Canada

Croma-Pharma GmbH, a prominent name in the sphere of minimally invasive aesthetic medicine, has recently unveiled its strategic partnership with Renellence, a key player in the Canadian aesthetic medicine market. This collaboration not only enhances Croma's footprint in Canada but also heralds exciting new prospects for aesthetic healthcare within the nation.

A Commitment to Quality and Innovation

The essence of this partnership lies in mutual dedication to excellence and innovative practices in aesthetic medicine. As part of this agreement, Renellence will take charge of distributing Croma’s MDR-approved Saypha® product line, which includes advanced hyaluronic acid fillers like Saypha® Filler, Saypha® Volume, and Saypha® Volume Plus across Canada. This move is poised to significantly widen access to Croma’s scientifically backed and high-quality solutions, enabling healthcare providers to offer top-tier aesthetic treatments to their clientele.

Andreas Prinz, the CEO of Croma-Pharma GmbH, expressed enthusiasm about the partnership, stating, "Canada has always been a vital market for Croma-Pharma, and we take pride in our contributions to this market over the years. Collaborating with Renellence allows us to merge our international expertise with their substantial local knowledge, positioning us for sustained success in Canada."

Focus on Medical Education and Training

In addition to expanding distribution, this partnership is set to prioritize the strengthening of medical education and training for healthcare professionals in Canada. Both Croma and Renellence will emphasize the importance of safe and effective patient outcomes, ensuring that practitioners are well-equipped with the knowledge and skills needed to administer Croma's products safely and efficiently. Renellence's CEO, Aria Moghimi, acknowledged the significance of this partnership, noting, "Croma is globally recognized for its commitment to quality and safety, and with Saypha® products, we aim to reshape the aesthetics landscape in Canada. Together, our goal is to drive a transformation in aesthetic medicine practices across the nation."

About Croma-Pharma GmbH

Croma-Pharma GmbH is a family-owned enterprise and a leading player in the minimally invasive aesthetics territory, headquartered in Leobendorf, Austria. The company focuses on the industrial production of hyaluronic acid injections and boasts a diverse aesthetic portfolio that includes botulinum toxin, fillers, PDO threads, PRP, and skin care technologies. With a presence in over 80 global markets, Croma is a symbol of innovation and quality in aesthetic medicine.

About Renellence

Renellence Inc. is a dedicated Canadian aesthetics company committed to delivering scientifically validated and clinically safe products to the medical aesthetics field. By ensuring that its offerings meet the highest international standards, Renellence aims to facilitate a seamless connection between groundbreaking global advances and practical clinical applications in Canada. The company aims to improve patient outcomes while fostering the growth of the aesthetics industry.

In conclusion, the partnership between Croma-Pharma and Renellence signifies a promising development in the realm of aesthetic medicine in Canada. Together, they aspire to set new benchmarks of excellence, innovation, and safety in the industry.